Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021

Study Results Successfully Inform the Design of ATH434 Phase 2 Clinical Trial MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Alterity Therapeu...

Full "IntellAsia: Resources" article